Using advanced techniques to identify causes of uveitis
Official title: Programmable Phage Display Peptidomes to Characterize Uveitis
Funded at University of California, San Francisco · NIH-10993534 · Data updated 2026-11-12
This study is looking at how to better diagnose and treat uveitis, a serious eye condition that can cause vision loss, by using new technology to find specific markers in the eye fluids of patients, which could help doctors provide more accurate care.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $246,000 |
| NIH project number | 1R21EY036683-01 |
| Project ID | NIH-10993534 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with anterior uveitis or have suspected viral-associated uveitis.
✕Less likely to help
Patients with uveitis caused by known factors or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on understanding uveitis, a group of eye diseases that can lead to blindness if not properly diagnosed and treated. The team will utilize innovative programmable phage display technology to identify specific autoantigens and antibodies in the eye fluids of patients suffering from anterior uveitis. By analyzing samples from patients with idiopathic and viral-associated uveitis, the researchers aim to discover new biomarkers that can improve diagnostic accuracy and treatment options. This approach combines high-throughput sequencing with advanced bioassays to enhance our understanding of the disease.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic methods for uveitis, ultimately reducing the risk of blindness for patients.
How similar studies have gone: While the use of phage display technology is well-established in other fields, its application in uveitis diagnostics is novel and has not been extensively tested.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Doan, Thuy a — University of California, San Francisco
- Study coordinator: Doan, Thuy a
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.